AMAG AMAG Pharmaceuticals, Inc.

24.15
-0.05  -0.21%
Previous Close 24.20
Open 24.10
Price To book 0.89
Market Cap 827.23M
Shares 34,254,000
Volume 709,710
Short Ratio 3.61
Av. Daily Volume 1,333,590

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

NDA filing due early 2018.
Rekynda
Hypoactive sexual desire disorder (HSDD)
Phase 3 trial to be completed estimated 1Q 2017. sNDA due mid 2017.
Feraheme
Adults with iron deficiency anemia (IDA)
Pharmacokinetic (PK) data released February 2, 2017. sNDA filing due 2Q 2017.
Makena - auto injector
Reduce the risk of preterm birth in women with a singleton pregnancy

Latest News

  1. AMAG Pharmaceuticals, Inc. -- Moody's revises outlook on AMAG to stable, affirms B2 CFR
  2. AMAG PHARMACEUTICALS INC. Files SEC form 10-K, Annual Report
  3. AMAG Pharmaceuticals, Inc. :AMAG-US: Earnings Analysis: 2016 By the Numbers : February 16, 2017
  4. AMAG Pharmaceuticals Inks $60M Drug Deal
  5. AMAG Pharmaceuticals, Inc. :AMAG-US: Earnings Analysis: Q4, 2016 By the Numbers : February 15, 2017
  6. AMAG Pharma (AMAG) Incurs Loss in Q4, Revenues Lag Estimates
  7. Edited Transcript of AMAG earnings conference call or presentation 14-Feb-17 1:00pm GMT
  8. Biotech Premarket Movers: Pacific Biosciences of California, AMAG, Global Blood Therapeutics
  9. AMAG Pharmaceuticals Inc Earnings Call scheduled for 8:00 am ET today
  10. AMAG Pharmaceuticals reports 4Q loss
  11. AMAG Pharmaceuticals reports 4Q loss
  12. AMAG PHARMACEUTICALS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Results of Operations and F
  13. Q4 2016 AMAG Pharmaceuticals Inc Earnings Release - Before Market Open
  14. AMAG Reports Fourth Quarter and Full Year 2016 Financial Results
  15. AMAG and Endoceutics Enter Into an Exclusive U.S. License Agreement for Intrarosa™ (Prasterone)
  16. AMAG Pharmaceuticals to Present at Upcoming Investor Conference
  17. AMAG Pharmaceuticals to Host Fourth Quarter and Full Year 2016 Financial Results Conference Call and Webcast on Tuesday, February 14, 2017 at 8:00 a.m. ET
  18. AMAG PHARMACEUTICALS INC. Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Regulation FD Discl
  19. AMAG Down Despite Positive Data on Makena Auto-Injector
  20. AMAG Pharmaceuticals Announces Closing of Exclusive Licensing Agreement for North American Rights to Rekynda™ (bremelanotide)